PMID- 27735951
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20240326
IS  - 2041-4889 (Electronic)
VI  - 7
IP  - 10
DP  - 2016 Oct 13
TI  - MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating 
      nuclear factor 90/vascular endothelial growth factor A axis.
PG  - e2413
LID - 10.1038/cddis.2016.306 [doi]
AB  - Altered expression of microRNA-590-5p (miR-590-5p) is involved in tumorigenesis, 
      however, its role in colorectal cancer (CRC) remains to be determined. In this 
      study, we focused on examining the effects of different expression levels of 
      miR-590-5p in cancer cells and normal cells. Results showed that there are lower 
      expression levels of miR-590-5p in human CRC cells and tissues than in normal 
      control cells and tissues. Similarly, in our xenograft mouse model, knockdown of 
      miR-590-5p promoted the progression of CRC. However, an overexpression of 
      miR-590-5p in the mice inhibited angiogenesis, tumor growth, and lung metastasis. 
      Nuclear factor 90 (NF90), a positive regulator of vascular endothelial growth 
      factor (VEGF) mRNA stability and protein synthesis, was shown to be a direct 
      target of miR-590-5p. The overexpression of NF90 restored VEGFA expression and 
      rescued the loss of tumor angiogenesis caused by miR-590-5p. Conversely, the 
      NF90-shRNA attenuated the increased tumor progression caused by the miR-590-5p 
      inhibitor. Clinically, the levels of miR-590-5p were inversely correlated with 
      those of NF90 and VEGFA in CRC tissues. Furthermore, knockdown of NF90 lead to a 
      reduction of pri-miR-590 and an increase of mature miR-590-5p, suggesting a 
      negative feedback loop between miR-590-5p and NF90. Collectively, these data 
      establish miR-590-5p as an anti-onco-miR that inhibits CRC angiogenesis and 
      metastasis through a new mechanism involving NF90/VEGFA signaling axis, 
      highlighting the potential of miR-590-5p as a target for human CRC therapy.
FAU - Zhou, Qingxin
AU  - Zhou Q
AD  - Department of Gastrointestinal Oncology, The Third Affiliated Hospital, Harbin 
      Medical University, Harbin, China.
FAU - Zhu, Yuekun
AU  - Zhu Y
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Wei, Xiaoli
AU  - Wei X
AD  - Department of Gastrointestinal Oncology, The Third Affiliated Hospital, Harbin 
      Medical University, Harbin, China.
FAU - Zhou, Jianhua
AU  - Zhou J
AD  - Department of Gastrointestinal Oncology, The Third Affiliated Hospital, Harbin 
      Medical University, Harbin, China.
FAU - Chang, Liang
AU  - Chang L
AD  - Department of Neurosurgery, The Third Affiliated Hospital, Harbin Medical 
      University, Harbin, China.
FAU - Sui, Hong
AU  - Sui H
AD  - Department of Gastrointestinal Oncology, The Third Affiliated Hospital, Harbin 
      Medical University, Harbin, China.
FAU - Han, Yu
AU  - Han Y
AD  - Department of Gastrointestinal Oncology, The Third Affiliated Hospital, Harbin 
      Medical University, Harbin, China.
FAU - Piao, Daxun
AU  - Piao D
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Sha, Ruihua
AU  - Sha R
AD  - Department of Digestive Disease, Hongqi Hospital, Mudanjiang Medical University, 
      Mudanjiang, China.
FAU - Bai, Yuxian
AU  - Bai Y
AD  - Department of Gastrointestinal Oncology, The Third Affiliated Hospital, Harbin 
      Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161013
PL  - England
TA  - Cell Death Dis
JT  - Cell death & disease
JID - 101524092
RN  - 0 (MIRN590 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Nuclear Factor 90 Proteins)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Animals
MH  - Carcinogenesis/genetics/pathology
MH  - Cell Line, Tumor
MH  - Chickens
MH  - Colorectal Neoplasms/*blood supply/*genetics/pathology
MH  - Down-Regulation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - HEK293 Cells
MH  - Human Umbilical Vein Endothelial Cells/metabolism
MH  - Humans
MH  - Male
MH  - Mice, SCID
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neovascularization, Pathologic/*genetics/pathology
MH  - Nuclear Factor 90 Proteins/*genetics/metabolism
MH  - *Signal Transduction
MH  - Survival Analysis
MH  - Vascular Endothelial Growth Factor A/*genetics/metabolism
PMC - PMC5133975
EDAT- 2016/10/14 06:00
MHDA- 2017/08/02 06:00
PMCR- 2016/10/01
CRDT- 2016/10/14 06:00
PHST- 2016/04/07 00:00 [received]
PHST- 2016/08/16 00:00 [revised]
PHST- 2016/08/31 00:00 [accepted]
PHST- 2016/10/14 06:00 [entrez]
PHST- 2016/10/14 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2016/10/01 00:00 [pmc-release]
AID - cddis2016306 [pii]
AID - 10.1038/cddis.2016.306 [doi]
PST - epublish
SO  - Cell Death Dis. 2016 Oct 13;7(10):e2413. doi: 10.1038/cddis.2016.306.